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INTRODUCTION
Central line-associated bloodstream infections (CLA-BSIs) re-
main a significant cause of treatment-related morbidity, mortality,
and increased healthcare costs in hospitalized patients [1,2]. Over
the last decade, it has become increasingly evident that reliable
implementation of established, ‘‘simple’’ interventions, such as
hand-washing and procedural checklists, can reduce the incidence
of CLA-BSIs [1]. In 2004, the efficacy of five such interventions
in the adult intensive care unit (ICU) setting was reported [3].
Importantly, the interventions were accompanied by policies and
procedures that inculcated a culture of patient safety and health
care quality among the clinical care team [4]. The merits of these
processes were demonstrated in a landmark study of 108 ICUs
across the state of Michigan that led to significant reductions in
CLA-BSIs from a baseline of 7.7 infections per 1,000 catheter
days to 1.4 [5] which persisted up to 3 years after the interven-
tions were implemented [6], and was associated with improved
awareness [7].
Public reporting and pay-for-performance incentive programs
for quality measures have significantly encouraged improved
health care processes [8–10]. Notably, bundled central line care
practices have been used to provide an organized framework for
catheter insertion procedures, resulting in better outcomes
[11,12], although the majority of the work has been validated in
adult ICU patients. Recent reports have shown that it is possible
to attain a reduction in CLA-BSIs in pediatric ICUs, and even
across an entire pediatric hospital [13–16]. In contrast to the adult
ICU experience, the application of catheter insertion processes
alone was not sufficient to reduce infection rates in children.
The development and application of a central line maintenance
bundle reduced pediatric ICU CLA-BSI rates by almost half [14].
There has been growing interest in reducing the incidence of
CLA-BSIs outside of the ICU setting for both adults [17,18]
and children [19]. However, little is known of the applicability
of the interventions developed in the ICU to other care settings or
populations.
In the pediatric ICU setting, a primary oncologic diagnosis
more than doubles the risk of developing a CLA-BSI [20]. The
rate of CLA-BSIs among hospitalized pediatric hematology–on-
cology (PHO) patients has been reported to range from 2.3 to 4.6
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infections per 1,000 catheter days [21]. Accordingly, CLA-BSIs
may account for the single largest cause of nosocomial infections
in this high-risk population [22]. Furthermore, the risk of life-
threatening infection in these patients is potentially exacerbated
by prolonged neutropenia resulting from immunosuppressive che-
motherapy [23–25]. Other risk factors for the development of
CLA-BSIs that are common among children with cancer include
blood product exposure, parenteral nutrition, and younger age
[23,26–33]. Little data exist about effective approaches for reduc-
ing the incidence of CLA-BSIs in this vulnerable population. In
this study, we tested the hypothesis that implementing a bundled
set of care practices for the daily maintenance of central lines in
PHO patients would reduce the rate of CLA-BSIs. We further
hypothesized that iterative root cause analyses (RCA) of residual
CLA-BSIs in PHO patients would help refine the bundle and
identify additional prevention strategies.
METHODS
Study Setting
The PHO service at the University of Michigan Mott Child-
ren’s Hospital is a 26-bed unit. There are approximately 100 new
pediatric oncology diagnoses and over 600 admissions to the PHO
unit annually. The average daily census is 12 patients under the
PHO service and 7 patients under the blood and marrow trans-
plant (BMT) service. As a part of routine institutional infection
control practices, all PHO patients with a central line catheter in
place during their inpatient admission were prospectively fol-
lowed for the development of a CLA-BSI throughout the period
under analysis (January 2005 through June 2011). The institution-
al review board approved the study and waived the need for
informed consent.
Study Design
A multidisciplinary CLA-BSI Working Group was developed
in January 2008 with the aim to reduce the CLA-BSI rate in PHO
patients. This team included pediatric physicians specializing in
PHO, infectious diseases, anesthesiology, and surgery, as well as
an infection-control professional, a phlebotomy service leader,
and several PHO nursing leaders. During the first 4 months of
the project, the team members met regularly and received training
in the study design, the practice interventions, and the expected
effect of these interventions according to the CDC and Pediatric
ICU NACHRI Quality Transformation Efforts [14]. Team mem-
bers developed techniques to improve the safety culture associat-
ed with central line catheter care, identified best practices for the
insertion and maintenance of catheters, and disseminated the
information to clinical care providers. In May 2008, a central
line maintenance bundle specific to PHO/BMT patients was
implemented to promote adherence to key practices (Table I).
These catheter care practices were tailored to non-ICU, PHO
patients, and adapted to the general care inpatient setting. Main-
tenance bundle forms were distributed weekly to all bedside
nurses and served both as a retrospective audit (for care processes
already completed during the shift) as well as a prospective
checklist (to drive adherence to preferred standard practices in
the remainder of the shift).
In order to identify common factors in patients who developed
CLA-BSIs, a RCA was conducted for every CLA-BSI event.
Patient variables, catheter variables, contextual factors, and sys-
tem issues were systematically reviewed to characterize CLA-BSI
events and identify drivers and common themes. A summary of
the findings and the overall incidence of CLA-BSIs were
reviewed at monthly meetings. In July 2009 (14 months after
the initial intervention), power peripherally inserted central cath-
eters (PICC) were discontinued as a result of a suspected associa-
tion with CLA-BSIs. As part of ongoing Plan-Do-Study-Act
quality improvement work, daily chlorhexidine gluconate
(CHG) cleansing [34–36] was also implemented in January
2010 (20 months after the initial intervention).
Data Collection
The project’s process measure was maintenance bundle com-
pliance which was self-reported by bedside nurses through com-
pletion of the weekly forms. The project outcome measure was
the CLA-BSI rate, calculated by dividing the number of monthly
CLA-BSI events by the number of patient days (PD) in that
month. The Agency for Healthcare Research and Quality’s Hos-
pital Survey on patient safety culture was administered bi-annu-
ally and served as a contextual measure for the project.
CLA-BSIs were identified prospectively by a trained, hospital-
based, infection control professional following National Health-
care Safety Network (NHSN) methods [37]. The surveillance
methods and personnel utilized were consistent during the pre-
intervention and post-intervention phases, and determinations of
CLA-BSI events were made by an infection control professional
independently from the clinical team [38]. The NHSN definition
for CLA-BSI used to identify events during the study period
included the following common-practice modifications: (i) only
TABLE I. Central Line Catheter Maintenance Bundle
Hand hygiene
Proper hand cleansing before every catheter/tubing/dressing
interaction
Dressings changed appropriately
Recommended intervals: at 7 days for transparent dressings or
3 days for gauze
Other indications: soiled, damp, loose, unknown date/time of
last change
Recommended practices: chlorhexidine gluconate skin antisepsis
when dressing changed
Intravenous tubing changed appropriately
Recommended intervals: at 96 hours since last tubing change or
24 hours if blood/lipid exposure
Other indications: Medication hang-time expiration, unknown
date/time of last change
Bathing or showering performed
Chlorhexidine used for bath or shower
Dressing and catheter covered during bath or shower
Dressing changed immediately after bath or shower if dressing
change due by date
Caps/tape changed on unaccessed lumens after bath or shower
Central lines entered appropriately
Minimized entries through batching of medication administration
and lab draws
Maintained closed intravenous system (e.g., pre-pierced ports/caps,
and bifuse extension sets)
Cleansed access points with alcohol scrub prior to each line entry
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laboratory confirmed primary bloodstream infections were includ-
ed; (ii) the date of onset was defined as the date of the first
positive blood culture; and (iii) CLA-BSIs identified in the first
48 hours of admission were excluded as present or incubating at
admission. In 2008 (during the study period), the NHSN definition
for CLA-BSI was revised, notably to require two positive cultures
for organisms considered to be common skin contaminants
[38,39]. To assess and correct for the effect of this change on
CLA-BSI determinations, all cases of CLA-BSI prior to 2008
were re-adjudicated using the revised 2008 definition.
Analysis
Between January 2005 and June 2011, the monthly CLA-BSI
rate was plotted on annotated control charts. After March 2008,
all-or-none compliance with central line maintenance practices
was collected and summarized by time period in tabular form.
Statistical process control was employed for real-time insight into
the data, and natural break points were identified through special
cause variation using the four conventional rules, at which point
mean lines were adjusted [40]. These mean lines were used to
establish early and late steady-state CLA-BSI rates. For the
purposes of this analysis, the CLA-BSI rates of two additional
time periods were defined and analyzed: pre-intervention
(January 2005–April 2008) and post-intervention (May 2008–
June 2011). Wilcoxon rank sum and t-tests were used as appro-
priate to generate P values.
RESULTS
CLA-BSI Rates and Blood Culture Isolates
The PHO CLA-BSI rate from 2005 through 2007 (pre-imple-
mentation) using the CDC/(NHSN) definition in effect at the time
was 3.59/1,000 patient-days (PD). Adjudication of the 80 CLA-
BSI cases prior to 2008 identified 12 that no longer met the
revised definition. Excluding cases not satisfying the updated
CDC/NHSN definition, the 2005–2007 CLA-BSI rate was 2.92/
1,000 PD, yielding an 18.6% rate reduction attributable to the
definition change alone. All further analyses were performed with
only cases meeting the current CDC/NHSN definition for analytic
consistency and contemporary relevance. Culture isolates are
summarized in Table II.
Bundle Compliance
Self-reported adherence to recommended maintenance bundle
practices was generally high (>90%) in most domains, both in the
early ramp-up period as well as during the later sustaining period,
and all-or-none compliance increase by 35% (Table III). The only
two domains with <90% compliance during the early ramp-up
period (bathing practices and strategies to reduce line entry) both
showed marked improvement over time. Pre-implementation
compliance data were not collected.
Subgroup Analysis
The CLA-BSI rate dropped significantly after bundle imple-
mentation in the PHO population overall, as well as in the BMT
and non-BMT subgroups (Table IV and Fig. 1). Out of 102 total
PHO CLA-BSIs, more than half (58%) occurred in BMT patients,
although BMT patients comprised a minority (30%) of PD. Over-
all, BMT patients were three times more likely to develop a CLA-
BSI per patient-day than non-BMT patients (P < 0.033). Howev-
er, comparing the late steady state rates, BMT patients were only
1.33 times as likely to develop a CLA-BSI than non-BMT
patients, and this difference lost statistical significance.
TABLE II. CLA-BSI Blood Culture Isolates 2005–2011, Based on
Revised NHSN Definition
All PHO Non-BMT BMT
Counts (n) (130) (60) (70)
Number of concurrent isolates % % %
One organism 72.7 67.4 76.8
Two organisms 22.2 20.9 23.2
Three organisms 5.1 11.6 —
Gram positive cocci 71.7 66.9 74.2
Staphylococcus 34.6 28.4 40.0
coagulase ()a 29.2 21.7 35.7
aureus 5.4 6.7 4.3
Streptococcus 21.6 23.4 18.5
pneumoniae 0.8 — 1.4
mitisa 10.8 15 7.1
alpha-hemolytic NOSa 6.2 6.7 5.7
oralisa 1.5 — 2.9
sanguisa 1.5 1.7 1.4
salvariusa 0.8 — 1.4
Enterococcus 14.7 13.4 15.7
faecalis 6.2 6.7 5.7
faecium 8.5 6.7 10
Micrococcusa 0.8 1.7 —
Gram negative bacilli 22.5 28.4 16.9
Pseudomonas 6.2 3.3 8.5
aeruginosa 5.4 3.3 7.1
oryzihabitans 0.8 — 1.4
Klebsiella 5.4 8.3 2.8
oxytoca 3.1 5 1.4
pneumonia 2.3 3.3 1.4
Enterobacter 3.1 5 1.4
cloacae 2.3 3.3 1.4
species NOS 0.8 1.7 —
Escherichia coli 3.1 6.7 —
Stenotrophomonas maltophilia 0.8 1.7 —
Acinetobacter species NOS 0.8 1.7 —
Alcaligenes xylosoxidans 0.8 — 1.4
Leptotrichia buccalis 0.8 — 1.4
Proteus mirabilis 1.5 1.7 1.4
Fungal 3.1 5.1 1.4
Candida 3.1 5.1 1.4
krusei 1.5 1.7 1.4
parapsilosis 0.8 1.7 —
glabrata 0.8 1.7 —
Gram positive bacilli 3.2 — 5.6
Bacillus cereusa 0.8 — 1.4
Clostridium perfringens 0.8 — 1.4
Lactobacillus species NOS 0.8 — 1.4
Microbacterium 0.8 — 1.4
NHSN, National Healthcare Safety Network; NOS, not otherwise
specified; aOrganisms considered to be common skin contaminants
in the revised NHSN definition; The revised NHSN definition re-
quired two positive blood cultures for organisms considered common
skin contaminants.
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CLA-BSI rates are displayed in annotated control chart format
in Figure 1 for the aggregate PHO population as well as the
BMT/non-BMT subgroups. All three control charts demonstrate
special cause variation consistent with the intended effects of the
prevention bundle, although signals emerged in different time-
frames. In the non-BMT population, significant CLA-BSI reduc-
tion occurred immediately following implementation of the
bundle. However, it was not until after elimination of power
PICCs and implementation of daily CHG bathing that a signifi-
cant and sustained CLA-BSI rate reduction was appreciated in the
BMT population.
Common Variables in the CLA-BSI RCA
Patient characteristics and catheter variables of those who met
the criteria for CLA-BSI following implementation of the main-
tenance bundle checklist are summarized in Table V. There were
36 CLA-BSI events that occurred in 32 patients. Four patients
experienced greater than one CLA-BSI. Twenty-one CLA-BSI
events occurred in BMT recipients (58%) and 15 in PHO patients
(42%). The median time from catheter insertion to CLA-BSI
event was 47 days (interquartile range, IQR, 15–116). The median
age of the study population was 12 years (IQR 4–18), and 72%
were male. The majority of patients had either hematologic ma-
lignancies (58%) or solid tumors (36%).
Safety Culture
The PHO nursing responses to the AHRQ Hospital Survey on
patient safety culture reflected improvement in nearly all domains
when comparing the pre-intervention with the post-intervention
data. This included positive perceptions of: overall unit safety
(rose from 40% to 89%, P < 0.07), organizational learning and
continuous improvement (rose from 64% to 85%, P < 0.31),
teamwork within the unit (rose from 79% to 95%, P < 0.37),
and hospital management support for patient safety (rose from
51% to 93%, P < 0.25). Survey sample sizes were small with low
response rates (12–32%), and comparisons did not meet statistical
significance.
DISCUSSION
Rapid improvements in health care performance metrics com-
monly result from the reliable implementation of evidence-based
science into daily practice more than implementing novel meth-
ods of care. The growing pressure to reduce nosocomial CLA-
BSIs has led to more effective adoption of evidence-based clinical
practice guidelines that have significantly improved patient
safety in both adult and pediatric ICU settings [5,14]. Herein,
we demonstrate that the application of daily maintenance catheter
care bundles to pediatric patients with an underlying diagnosis of
hematologic malignancy roughly halved CLA-BSIs. In contrast
to adult ICU experiences, where bedside percutaneous catheter
insertion practices are key drivers of CLA-BSI, our findings
reinforce the importance of daily catheter maintenance practices
for sustainably reducing rates of infection in catheters with pro-
longed dwell times. Three quarters of the CLA-BSIs we observed
occurred more than 2 weeks out from central line insertion.
The importance of daily catheter maintenance practices may
well hold true for the adult oncology population in whom





Self-reported compliance audits, count (n) 235 221
Dressing change practices 97% 99%
Intravenous tubing change practices 100% 99%
Bathing practices 57% 89%
Practices to reduce central line entries 71% 97%
Access point hygiene practices 97% 90%
Hand hygiene before all central line care and entries 98% 92%
All-or-none compliance (i.e., completely compliant) 51% 86%
TABLE IV. CLA-BSI Rates in All Patients and Subgroups, Pre- and Post-Intervention
All PHO BMT Non-BMT
Aggregate CLA-BSI events (n) (102) (57) (45)
Pre-intervention CLA-BSI ratea 2.92 5.55 1.81
Post-intervention CLA-BSI ratea 1.61 2.96 1.04
Pre/post-CLA-BSI rate reduction (%) 45% 47% 43%
P comparing pre- vs. post-intervention <0.004 <0.037 <0.035
Early steady state CLA-BSI ratea 2.77 5.25 1.82
Late steady state CLA-BSI ratea 1.23 1.33 1.00
Early/late CLA-BSI rate reduction (%) 56% 75% 45%
P comparing early vs. late steady state <0.002 <0.007 <0.007
PHO, pediatric hematology/oncology; BMT, blood and marrow transplant; CLA-BSI, central line-associated bloodstream infection; aRate
expressed as CLA-BSIs per 1,000 patient-days.
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CLA-BSIs temporally related to surgically implanted catheters are
also uncommon.
The early steady-state CLA-BSI rate for our entire study pop-
ulation was 2.77 per 1,000 PD, and within the BMT and non-
BMT patients, the rates were 5.25 and 1.82 per 1,000 PD, respec-
tively—nearly a threefold difference. In line with published
literature [41], we considered BMT as a potential risk factor for
CLA-BSI. Interestingly, during the late steady-state period, the
Fig. 1. CLA-BSI rate for all pediatric hematology/oncology and subsets.
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rates between the BMT and non-BMT patients were 1.33 (45%
reduction) and 1.00 (75% reduction) per 1,000 PD, respectively.
As time went on and further infection control strategies were
implemented, the CLA-BSI rate in BMT patients became insig-
nificantly different from non-BMT patients, demonstrating that
similar CLA-BSI outcomes can be achieved in these populations
despite their differences in risk [42].
In contrast to recent studies reporting decreased rates of CLA-
BSI with PICCs [43,44], we initially observed overrepresentation
of PICCs in our RCAs. Nine of seventeen CLA-BSIs were
associated with power PICCs within the first 14 months of
implementing bundled checklists. However, this finding should
be interpreted with caution as we eliminated these lines early in
the study period during process improvements. It is possible that
over time with further adherence to standardized catheter care
techniques, we would have observed similar CLA-BSI rates
across catheter types. Based on our RCA, there were no other
suggested associations between catheter variables (type, number
of lumens, and material) and the risk for developing CLA-BSIs. A
reduction in the BMT CLA-BSI rate was observed after cessation
of power PICCs and implementation of CHG bathing [34,36].
However, a causal relationship can only be inferred by temporal
association. The addition of CHG bathing may have led to uni-
form and better monitored bathing practices. Alternatively, it may
TABLE V. Characteristics of CLA-BSI Events (May 2008–June 2011)
Patient category, count (%)
All CLA-BSI events 36 100%
Occurring in BMT patients 21 58%
Occurring in non-BMT patients 15 42%
Patient demographics
Age in years, median (IQR) 12 [4–18]
Male:female, count (%) 26:10 72%:28%
Diagnosis, count (%)




Solid tumors 13 36%
Non-malignancy (aplastic anemia/PNH) 2 6%
Blood counts at time of CLA-BSI event
WBC in cells/ml, median (IQR) 250 100–2,075
Leukopenic with WBC <450 cells/ml, count (%) 28 78%
ANC in cells/ml, median (IQR) 0 0–1,650
Neutropenic with ANC <500 cells/ml, count (%) 24 67%
Temporal association to antecedent events, count (%)
Operation or procedure <7 days prior to CLA-BSI event 8 22%
Transfusions
Red blood cells <7 days prior to CLA-BSI event 27 75%
Platelets <7 days prior to CLA-BSI event 26 72%
Chemotherapy
<7 days prior to CLA-BSI event 21 58%
<30 days prior to CLA-BSI event 35 97%
Stem cell infusion
<7 days prior to CLA-BSI event 8 38%a
<30 days prior to CLA-BSI event 14 67%a
Post-BMT day number at time of CLA-BSI, median (IQR)b þ5 0 to þ15
Catheter dwell time prior to CLA-BSI event, median days (IQR) 47 15–116
Temporal association to subsequent events, count (%)
Patient death
<7 days after CLA-BSI event 1 3%
<30 days after CLA-BSI event 3 8%
Within the same hospitalization of CLA-BSI event 7 19%
Patient transfer to ICU <7 days after CLA-BSI event 8 22%
Catheter type, count (%)
Neostar 12 34%
Broviac 8 22%
Power PICC 9 25%
Port 4 11%
PICC, standard 3 8%
CLA-BSI, central line-associated bloodstream infection; BMT, blood and marrow transplant; IQR, interquartile range; ALL, acute lympho-
blastic leukemia; AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome; PNH, paroxysmal nocturnal hemoglobinuria; WBC,
white blood cell count; ANC, absolute neutrophil count; PICC, peripherally inserted central catheter; aPercentages are of events are among
BMT patients only; bOf 36 CLA-BSI events, 21 occurred in BMT patients of which 4 (19%) occurred between 1–3 days prior to transplant date.
CLA-BSI Reduction in Hospitalized Oncology Patients 267
Pediatr Blood Cancer DOI 10.1002/pbc
have coincided with a time period when standardized best-
catheter practices were more reliably established.
It is intuitive that children with cancer and blood disorders,
particularly those undergoing a BMT, would be at increased risk
for CLA-BSI because of their immunocompromised state. In fact,
the median WBC and ANC at the time of CLA-BSI in our patient
population were 250 and 0 ml1, respectively. However, despite
the severe neutropenia, our findings suggest that rigorous imple-
mentation of PHO-specific central line maintenance bundles re-
duced the incidence of CLA-BSIs significantly. Consistent with
published data [5,14,42], this reduction occurred without hiring
additional staff or significantly increasing nursing workload.
Nonetheless, our RCA findings suggest that future areas of study
are needed particularly regarding the apparent associations with
blood product transfusions, stem cell infusions, and male gender.
For instance, during periods of neutropenia, one could consider
prophylactically locking central lines with antibiotics [41] or
ethanol solutions [45,46] much as other neutropenic prophylaxis
is initiated in this population. Similarly, perhaps more rigorous
aseptic techniques for blood product transfusions should be
adopted during periods of neutropenia, such as more rapid
expiration of intravenous tubing exposed to blood products.
The CDC/NHSH definition for CLA-BSI changed in
January 2008, which led to an attributable rate reduction of
18% in our study population, consistent with other reports
[14,16,20,41]. The most common pathogen excluded as a likely
skin contaminant was coagulase-negative Staphylococcus (CNS).
Nonetheless, gram-positive bacteria still caused the majority of
CLA-BSI in our study, and CNS remained the predominant or-
ganism. It is possible that immunocompromised hosts are more
susceptible to less virulent isolates or microcontamination that
immune competent hosts might spontaneously clear [20]. Impor-
tantly, the revised CDC/NHSN definition is less sensitive to cath-
eters infected with common skin contaminants. While this may
reduce false positives in other care settings, it may falsely exclude
real line infections in immunocompromised children. In such
vulnerable populations, a clinical adjudication of CLA-BSI with
CNS or other skin flora should always be entertained, even if
infection control specialists would not categorize an event as a
laboratory-confirmed CLA-BSI.
There are several limitations of our study. First, given the
non-randomized study design and lack of controls, we cannot
conclude with certainty that the implementation of maintenance
bundle checklists was responsible for the reduction in CLA-BSIs,
nor that the temporal associations were causal. However, our
findings are consistent with successful implementation of evidence-
based practices. Second, the CDC definition of CLA-BSI primari-
ly relates to hospital-acquired bloodstream infections. As such,
our data do not capture PHO patients who acquire CLA-BSIs
on the outpatient setting and are then hospitalized for further
management. Similarly, the hospital-based surveillance system
functions by geography, not diagnostic category, so there were
undoubtedly a non-trivial number of CLA-BSIs that occurred in
this population, specifically in the pediatric ICU, that are not
reflected in our reported data. Therefore, the true incidence (as
well as the associated morbidity and mortality) of CLA-BSIs may
be underrepresented in our study. Third, CLA-BSI rates in our
PHO unit were expressed with a denominator of PD because
nearly all of our patients have central lines (catheter day data
were not collected). If our CLA-BSI rate were expressed in
central line days, our rate would likely be slightly higher. None-
theless, PD remained a consistent denominator throughout the
study period. Lastly, this is a single-institution study focused on
(i) transferring current evidence into new populations, (ii) identi-
fying local phenomena to guide specific quality improvement
countermeasures, and (iii) unit-level contextual forces that may
have facilitated success. Therefore, extrapolation to other PHO
units warrants careful consideration. Ongoing multi-center collab-
orative efforts in PHO units [47] should help further illuminate
reproducible best practices.
In summary, efforts to eradicate CLA-BSIs, which were
initially implemented in adult and pediatric ICUs [5,14] are
now being extended into other high-risk populations. Our study
supports that CLA-BSIs are also preventable in PHO patients. The
significant reduction is sustainable with day-to-day adherence to
evidence-based guidelines and continued re-evaluation of catheter
care practices. We developed an optimal maintenance bundle spe-
cific to our patient population, which required a multidisciplinary-
collaborative effort to enact. Over the 3-year post-implementation
period, our CLA-BSI incidence was significantly reduced by
eliminating defects in best practices through quality improvement
methods, specifically, multidisciplinary team-based problem solv-
ing, iterative RCA, and ongoing Plan-Do-Study-Act cycles. Nota-
bly, it is believed that the sustained reductions in CLA-BSI rates
in both patient populations resulted from: (i) promoting a culture
of patient safety, (ii) adopting uniform catheter care practices, (iii)
learning multidisciplinary teamwork, and (iv) communicating
effectively between patients, families, physicians, nurses, phlebot-
omists, and infection control specialists. Arenas where standard-
ized best practice catheter care guidelines could be studied in the
future include the outpatient clinical setting, home health inter-
faces, and in patients’ homes where families or the patients them-
selves are the catheter care providers.
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